Thursday, March 28, 2024 | Baltimore, MD
FOLLOW US:

United Therapeutics just earned a long-awaited FDA approval

May 24, 2022

United Therapeutics Corp.’s latest product just quietly earned long-awaited approval from the Food and Drug Administration — sending the local drugmaker’s stock soaring. The FDA issued a letter Monday denying a citizen position that sought to stop regulators from giving its nod to Tyvaso DPI, an inhaler that dispenses a dry powder form of treprostinil, the key ingredient for the pulmonary arterial hypertension (PAH) treatment.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.